IHMT-MST1-39
IHMT-MST1-39 is an orally active inhibitor for MST kinase, with IC50 of 42, 109, 286, 159 nM for MST1, MST2, MST3, MST4. IHMT-MST1-39 activates the AMPK signaling pathway in liver cells, reduces apoptosis of pancreatic β-cells. IHMT-MST1-39 can be used for the studies of type 1 diabetes (T1D) and type 2 diabetes (T2D) [1].
Product Specifications
CAS Number
2414484-01-6
UNSPSC
12352005
Target
AMPK; Apoptosis; Hippo (MST)
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/ihmt-mst1-39.html
Purity
99.68
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1N(C)C2=CN=C(NC3=CC=C(S(=O)(N)=O)C=C3)N=C2N(C1C4=C(F)C=CC=C4F)C
Molecular Formula
C20H18F2N6O3S
Molecular Weight
460.46
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MST1; MST2; MST3; MST4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD45 / LCA (2B11 + PD7/26), CF594 conjugate, 0.1mg/mL
Mucin 5AC (MUC5AC) (58M1), CF647 conjugate, 0.1mg/mL
CD3e (T-Cell Marker) (C3e/1931), CF488A conjugate, 0.1mg/mL
Catenin, beta (CTNNB1) (CTNNB1/2030R), CF488A conjugate, 0.1mg/mL
